Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$7.92
+2.3%
$6.78
$4.45
$8.12
$1.85B0.832.61 million shs3.36 million shs
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.88
+1.5%
$0.81
$0.66
$2.43
$102.02M0.862.66 million shs1.68 million shs
Endo International plc stock logo
ENDP
Endo International
$0.45
$0.28
$7.07
$141K1.1528.19 million shs9,967 shs
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$16.70
$16.59
$4.24
$16.72
$380.09M0.55157,287 shsN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$37.08
-1.6%
$36.18
$16.65
$46.48
$5.89B1.912.88 million shs957,478 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
+4.53%+12.94%+8.53%+34.93%+10.04%
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-0.12%+8.26%+7.70%+3.74%-39.36%
Endo International plc stock logo
ENDP
Endo International
0.00%0.00%0.00%0.00%0.00%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00%0.00%0.00%0.00%0.00%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-0.66%+1.26%-4.46%+2.62%+83.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
3.0754 of 5 stars
1.25.00.04.91.80.00.6
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
3.7528 of 5 stars
3.31.00.04.50.62.50.6
Endo International plc stock logo
ENDP
Endo International
0.4592 of 5 stars
0.00.00.03.51.11.70.0
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
4.0313 of 5 stars
2.41.00.03.53.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.40
Hold$7.70-2.72% Downside
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$4.68432.20% Upside
Endo International plc stock logo
ENDP
Endo International
0.00
N/AN/AN/A
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00
N/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$43.8018.12% Upside

Current Analyst Ratings Breakdown

Latest BKD, TGTX, ENDP, CHRS, and ORTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$37.00
7/9/2025
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
5/8/2025
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.00
4/29/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/24/2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.05
4/16/2025
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $7.50
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.16B0.59$0.88 per share8.95$1.07 per share7.40
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$272.25M0.37$0.30 per share2.98($1.14) per share-0.77
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00N/A0.06($13.60) per share0.00
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$22.66M16.77N/AN/A$7.74 per share2.16
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329M17.89$0.12 per share316.10$1.43 per share25.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$201.93M-$1.04N/AN/AN/A-7.52%-79.84%-3.33%8/14/2025 (Estimated)
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$28.51M-$1.13N/AN/AN/A-66.30%N/A-26.51%8/6/2025 (Estimated)
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/A
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.24154.5037.08N/A10.13%18.88%7.05%8/5/2025 (Estimated)

Latest BKD, TGTX, ENDP, CHRS, and ORTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.27N/AN/AN/A$147.76 millionN/A
5/12/2025Q1 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.35-$0.04-$0.49$59.79 million$7.60 million
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
5/6/2025Q1 2025
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.11-$0.11N/A-$0.28$816.16 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
28.85
0.82
0.82
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/A
1.22
1.20
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.20
3.12
2.98
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.03
4.02
3.04
CompanyEmployeesShares OutstandingFree FloatOptionable
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
36,000234.35 million230.13 millionOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330115.93 million106.57 millionOptionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
16622.76 million22.10 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million141.86 millionOptionable

Recent News About These Companies

TG Therapeutics, Inc. (TGTX) - Yahoo Finance
Cramer's Lightning Round: TG Therapeutics is a buy
TGTX - TG Therapeutics Inc Financials - Morningstar
TGTX - TG Therapeutics Inc Valuation - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brookdale Senior Living stock logo

Brookdale Senior Living NYSE:BKD

$7.92 +0.18 (+2.26%)
Closing price 03:58 PM Eastern
Extended Trading
$7.93 +0.01 (+0.19%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.

Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$0.88 +0.01 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$0.88 +0.00 (+0.34%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Endo International stock logo

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Orchard Therapeutics stock logo

Orchard Therapeutics NASDAQ:ORTX

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$37.08 -0.59 (-1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$37.16 +0.08 (+0.22%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.